AIToday
RoboticsAI in HealthcareAI Business & IndustryRobotics & Automation NewsPublished: Nov 23, 2026, 04:00 JST

Remedy Robotics raises $62 million for AI surgery robot

Send on LINE
Remedy Robotics raises $62 million for AI surgery robot

3 Key Points

  1. What happened

    Remedy Robotics raised $62 million in Series B funding led by DCVC, with UC Investments, Skip Capital and Hostplus participating, to support clinical trials and regulatory approval for its AI-enabled N1 System for cardiovascular and neurovascular procedures.

  2. Why it matters

    The funding will support clinical trials, regulatory approval efforts and further development of the robotic platform, which is designed to enable endovascular procedures through on-site, remote and potentially autonomous operation.

WHO IT HITSThis funding affects hospitals and clinicians who perform endovascular procedures, particularly in regions where qualified intervention specialists are unavailable, as Remedy aims to expand access to specialist treatment for stroke and other cardiovascular emergencies.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Context & Analysis

Remedy Robotics has been working with the University of California's clinical experts since 2021, according to CTO and co-founder Jake Sganga, and now plans a pivotal clinical trial across the UC network as it works toward potential FDA approval for neurovascular intervention. The company says it works with more than 100 hospitals worldwide and plans to introduce prototype systems across its clinical partner network.

In October 2025, Remedy reported completing remote neurointerventional procedures using the N1 System. The funding is aimed at supporting clinical trials, regulatory approval efforts and further development of the platform, which remains under development and is not approved for sale or clinical use in any jurisdiction. CEO and co-founder Dr. David Bell says the funding will allow Remedy to accelerate toward deployment of the N1 System so it can bring quality intervention to patients everywhere, regardless of geography.

FAQ
Who led the funding round?
The round was led by DCVC, with participation from UC Investments, Skip Capital and Hostplus, and existing investors including Build Collective, Blackbird, Divergent Capital and KdT Ventures also participated.
What is the N1 System designed to do?
The N1 System combines robotics, machine learning and computer vision to analyze preoperative imaging, simulate procedures and provide real-time image registration, and is designed to enable endovascular procedures through on-site, remote and potentially autonomous operation.
Is the N1 System approved for clinical use?
No, the N1 System remains under development and is not approved for sale or clinical use in any jurisdiction.
Robotics & Automation NewsRead Original Article
Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleNicalis pulls AI music from Binding of Isaac after backlash